

## 2023 ACR Pediatric Rheumatology Symposium Faculty Disclosures Word

---

The following types of relationships may be deemed relevant include:

1. Advisor or Review Panel Member
2. Consultant
3. Employee
4. Officer or Board Member
5. Grant/Research Support
6. Speaker/Honoraria (includes speakers bureau, symposia, and expert witness)
7. Independent Contractor
8. Ownership Interest
9. Royalties
10. Intellectual Property/Patents
11. Stock options or bond holdings in a for-profit corporation or self-directed pension plan
12. Other Financial or Material Support

*\*All of the relevant financial relationships listed for the meeting faculty have been mitigated.*

**Akinsete, Alisha, MD**

PRSYM23: Q&A Panel Discussion

Role: Virtual Speaker

PRSYM23: Suggestions to Mitigate Disparities in Clinical Care

Role: Virtual Speaker

Disclosure: No financial relationships with ineligible companies to disclose

**Ardalan, Kaveh, MD, MS**

PRSYM23: Utilizing PROMIS Measures in Juvenile Dermatomyositis

Role: Speaker

Disclosure: No financial relationships with ineligible companies to disclose

**Ardoin, Stacy, MD**

PRSYM23: Cardiovascular Effects in Pediatric Rheumatic Diseases

Role: Moderator

PRSYM23: Committee Member Disclosure

Role: Committee Member

PRSYM23: Opening Session - Keynote

Role: Speaker

Disclosure: No financial relationships with ineligible companies to disclose

**Özen, Seza, MD, MSc**

PRSYM23: Updates on Treatment of Takayasu's Arteritis

Role: Speaker

Disclosure: Novartis, 2 (Terminated); SOBI, 2 (Ongoing)

## 2023 ACR Pediatric Rheumatology Symposium Faculty Disclosures Word

---

**Balevic, Stephen, MD, PhD, RhMSUS**

PRSYM23: Precision Therapeutics: Describe the Principles of Pharmacogenetic Testing and the Clinical Guidelines Currently Available

Role: Virtual Speaker

Disclosure: Purdue Pharma, 5 (Terminated, June 30, 2022); UCB, 2 (Terminated)

**Baxter, Sarah, MD, PhD**

PRSYM23: Genetics in Childhood-Onset Lupus: Monogenic Diseases, Polygenic Models, Risk-Alleles and The Integration of Omics Data

Role: Speaker

Disclosure: Nanostring, 5 (Ongoing), 11 (Ongoing); ProventionBio, 3 (Ongoing)

**Benseler, Susanne (Susa), MD, PhD, FRCPC**

PRSYM23: cPACNS: Quality of Life and Cognitive Outcomes in Childhood Cerebral Vasculitis

Role: Speaker

Disclosure: No financial relationships with ineligible companies to disclose

**Bermas, Bonnie, MD**

PRSYM23: Reproductive Health in Rheumatic Diseases: What a Pediatric Rheumatologist Needs to Know

Role: Speaker

Disclosure: No financial relationships with ineligible companies to disclose

**Binstadt, Bryce, MD, PhD**

PRSYM23: Committee Member Disclosure

Role: Committee Member

PRSYM23: Novel Treatments

Role: Moderator

PRSYM23: Opening Session - Keynote

Role: Moderator

PRSYM23: Opening Session - The Big Picture

Role: Moderator

PRSYM23: Viruses and Autoimmunity

Role: Moderator

PRSYM23: Welcome and Opening Remarks

Role: Speaker

Disclosure: Pfizer, 5 (Ongoing); Sobi, 5 (Ongoing)

**Boyd, Stacey**

PRSYM23: Committee Member Disclosure

Role: Staff

Disclosure: No financial relationships with ineligible companies to disclose

## 2023 ACR Pediatric Rheumatology Symposium Faculty Disclosures Word

---

**Bridges, John, MD**

Plenary Session: The Bridge to Adult Care from Childhood for Young Adults with Rheumatic Disease (BACC YARD) Program, a Pediatric-to-Adult Rheumatology Transition Program

Role: Presenting Author

Disclosure: No financial relationships with ineligible companies to disclose

**Brown, Ryan, PhD**

PRSYM23: Psychoneuroimmunology Concepts and Stress/Mental Health in Pediatric Rheumatology

Role: Speaker

Disclosure: No financial relationships with ineligible companies to disclose

**Burnham, Jon, MD, MS**

PRSYM23: Utilization of Patient-Reported Outcomes in Quality Improvement Research

Role: Speaker

Disclosure: GlaxoSmithKlein(GSK), 5 (Terminated, December 31, 2022)

**Chang, Joyce, MD, MS**

PRSYM23: Listening for The Silent Killer: Assessment of Subclinical Cardiovascular Disease in Children with Lupus in Practice and Research

Role: Speaker

Disclosure: GSK, 5 (Terminated, December 31, 2022)

**Ciurtin, Coziana, MD, PhD, MSc, FRCP**

PRSYM23: Biomarkers for CV Disease Risk Stratification in Children and Adolescents with Lupus

Role: Speaker

Plenary Session: Re-analysis of the APPLE (Atherosclerosis Prevention in Pediatric Lupus Erythematosus) Trial Identifies Novel Determinants of Patient Heterogeneity and a Distinct Lipid Metabolomic Signature of Atherosclerosis Progression

Role: Presenting Author

Disclosure: GlaxoSmithKlein(GSK), 5 (Ongoing); UCB, 6 (Terminated)

**Cooper, Ashley, MD**

PRSYM23: Management of Uveitis: Refractory Disease and Treatment Withdrawal

Role: Speaker

Disclosure: No financial relationships with ineligible companies to disclose

**Donaldson, Brit, MMS, PA-C**

PRSYM23: Committee Member Disclosure

Role: Committee Member

Disclosure: No financial relationships with ineligible companies to disclose

## 2023 ACR Pediatric Rheumatology Symposium Faculty Disclosures Word

---

**Gilbert, Mileka, MD, PhD**

PRSYM23: Health Disparities in Pediatric Rheumatology and Strategies to Mitigate Their Effects

Role: Moderator

Disclosure: No financial relationships with ineligible companies to disclose

**Gmuca, Sabrina, MD, MSc**

PRSYM23: Resilience in Pediatric Rheumatology

Role: Speaker

Disclosure: No financial relationships with ineligible companies to disclose

**Gorelik, Mark, MD**

PRSYM23: Heart on Fire: Immunobiology of Cardiovascular Inflammation in Rheumatic Disease

Role: Speaker

Disclosure: No financial relationships with ineligible companies to disclose

**Grom, Alexei, MD**

PRSYM23: Committee Member Disclosure

Role: Committee Member

PRSYM23: Systemic Juvenile Idiopathic Arthritis

Role: Moderator

PRSYM23: Lung Disease in Systemic Juvenile Idiopathic Arthritis

Role: Speaker

Disclosure: Novartis, 1 (Ongoing), 2 (Ongoing), 5 (Ongoing); Sobi, 1 (Ongoing), 2 (Ongoing), 5 (Ongoing)

**Harper, Lauren, MD**

Plenary Session: Implementation of Automated Depression Screening in Patients with Lupus in a Tertiary Pediatric Rheumatology Clinic

Role: Presenting Author

Disclosure: No financial relationships with ineligible companies to disclose

**Hause, Emily, MD, MPH**

Plenary Session: Inflammation or Infection? Understanding Linguistic and Cultural Nuances Impacting the Care of Somali Children with Juvenile Idiopathic Arthritis

Role: Presenting Author

Disclosure: No financial relationships with ineligible companies to disclose

**Hernandez, Alejandra "Alex"**

PRSYM23: Committee Member Disclosure

Role: Committee Member

Disclosure: No financial relationships with ineligible companies to disclose

## 2023 ACR Pediatric Rheumatology Symposium Faculty Disclosures Word

---

**Hersh, Aimee, MD**

PRSYM23: Patient-Reported Outcomes: Patient Care and Research

Role: Speaker

Disclosure: No financial relationships with ineligible companies to disclose

**Hiraki, Linda, MD, FRCPC, ScD**

PRSYM23: Mental Health in Pediatric Rheumatology

Role: Moderator

Disclosure: Janssen, 2 (Ongoing)

**Horton, Daniel, MD, MS**

PRSYM23: Committee Member Disclosure

Role: Committee Member

PRSYM23: Juvenile Idiopathic Arthritis

Role: Moderator

Disclosure: Danisco USA, Inc., 5 (Ongoing)

**Horwitz, Marc**

PRSYM23: Mechanisms of Virus-Induced Autoimmunity

Role: Speaker

Disclosure: No financial relationships with ineligible companies to disclose

**Jackson, Shaun, MD, PhD**

PRSYM23: Committee Member Disclosure

Role: Committee Member

PRSYM23: Systemic Lupus Erythematosus

Role: Moderator

Disclosure: No financial relationships with ineligible companies to disclose

**Knight, Andrea, MD**

PRSYM23: Committee Member Disclosure

Role: Committee Member

PRSYM23: Panel Discussion

Role: Moderator

PRSYM23: Opening Session - Keynote

Role: Moderator

PRSYM23: Opening Session - The Big Picture

Role: Moderator

Disclosure: No financial relationships with ineligible companies to disclose

## 2023 ACR Pediatric Rheumatology Symposium Faculty Disclosures Word

---

### **Lawson, Erica, MD**

PRSYM23: Committee Member Disclosure

Role: Committee Member

PRSYM23: Transitional & Reproductive Care

Role: Moderator

Disclosure: No financial relationships with ineligible companies to disclose

### **Levy, Deborah, MD, MS**

PRSYM23: Clinical Management/Treat to Target

Role: Moderator

PRSYM23: Committee Member Disclosure

Role: Committee Member

Plenary Session: Remotely Delivered Psychological Intervention May Be Beneficial to Youth with Childhood-Onset Lupus: A Preliminary Investigation

Role: Presenting Author

PRSYM23: Precision Therapeutics

Role: Moderator

PRSYM23: Telehealth

Role: Moderator

Disclosure: AbbVie/Abbott, 1 (Terminated, December 31, 2021); Janssen, 1 (Terminated, December 31, 2021), 2 (Terminated, December 31, 2021); Medexus, 1 (Terminated, December 31, 2021), 6 (Terminated, December 31, 2021); SOBI, 1 (Ongoing), 5 (Ongoing)

### **Mann, Keith, MD**

PRSYM23: American Board of Pediatrics (ABP) Maintenance of Certification Session

Role: Speaker

Disclosure: No financial relationships with ineligible companies to disclose

### **Mannion, Melissa, MD**

PRSYM23: Management of Refractory Juvenile Idiopathic Arthritis

Role: Speaker

Disclosure: No financial relationships with ineligible companies to disclose

### **Marsh, Rebecca**

PRSYM23: Allogeneic Bone Marrow Transplant for Refractory Rheumatic Diseases

Role: Speaker

Disclosure: Horizon, 1 (Ongoing)

### **Mellins, Elizabeth, MD**

PRSYM23: Systemic JIA and Lung Disease: An Update

Role: Virtual Speaker

Disclosure: Codexis, Inc, 5 (Ongoing); Genentech, 5 (Terminated, February 20, 2023); GlaxoSmithKlein(GSK), 5 (Ongoing); Novartis, 5 (Terminated, February 20, 2023)

## 2023 ACR Pediatric Rheumatology Symposium Faculty Disclosures Word

---

**Mieszkalski, Kelly, MA**

PRSYM23: Committee Member Disclosure

Role: Committee Member

Disclosure: No financial relationships with ineligible companies to disclose

**Neely, Jessica, MD**

PRSYM23: Immune Dysregulation in Juvenile Dermatomyositis

Role: Speaker

Disclosure: No financial relationships with ineligible companies to disclose

**Nigrovic, Peter, MD**

PRSYM23: Non-Coding Causal Variants in Systemic Lupus Erythematosus

Role: Speaker

Disclosure: Merck/MSD, 2 (Ongoing)

**Ong, Mei-Sing, PhD**

PRSYM23: Artificial Intelligence/Machine Learning

Role: Speaker

Disclosure: No financial relationships with ineligible companies to disclose

**Pooni, Rajdeep, MD, MS**

PRSYM23: Telemedicine and Virtual Health: Future Use

Role: Speaker

Disclosure: No financial relationships with ineligible companies to disclose

**Quinn, Kaitlin, MD, MHS**

PRSYM23: Advanced Imaging in Takayasu's Arteritis

Role: Speaker

Disclosure: No financial relationships with ineligible companies to disclose

**Rao, Deepak, MD, PhD**

PRSYM23: Single Cell Omics

Role: Speaker

Disclosure: Aditum, 2 (Ongoing); Seeker Biologics, 2 (Ongoing)

**Rider, Lisa, MD**

PRSYM23: An Update on Autoantibodies in Juvenile Myositis

Role: Speaker

Disclosure: Argenix, 1 (Terminated, June 1, 2022); Bristol-Myers Squibb (BMS), 5 (Terminated); CabalettaBio, 1 (Ongoing); CSL Behring, 1 (Ongoing); Hope Pharmaceuticals, 5 (Ongoing); Horizon Therapeutics, 1 (Ongoing); Pfizer, 1 (Ongoing)

## 2023 ACR Pediatric Rheumatology Symposium Faculty Disclosures Word

---

**Roberts, Jordan, MD, MPH**

Plenary Session: Serious Infections Among Children with Systemic Lupus Erythematosus in the Pediatric Health Information System

Role: Presenting Author

Disclosure: No financial relationships with ineligible companies to disclose

**Roth, Johannes, MD, PhD, FRCPC, RhMSUS**

PRSYM23: Can US Guide Treat to Target?

Role: Speaker

Disclosure: No financial relationships with ineligible companies to disclose

**Rouster-Stevens, Kelly, MD, MS**

PRSYM23: Committee Member Disclosure

Role: Committee Member

PRSYM23: Juvenile Dermatomyositis and Scleroderma

Role: Moderator

Disclosure: Accordant, 1 (Ongoing)

**Sagcal-Gironella, A. Carmela, MD, MS**

PRSYM23: Therapeutic Drug Monitoring in Pediatric Rheumatology: Time for Tailored Therapy?

Role: Speaker

Disclosure: Novartis, 1 (Terminated, November 19, 2021)

**Scott, Chris, MBChB**

PRSYM23: Committee Member Disclosure

Role: Committee Member

Disclosure: Ipsen, 6 (Ongoing); Janssen, 6 (Terminated); Pfizer, Conference support in 2022 (Terminated), 6 (Terminated)

**Smith, Eve, MD, PhD, BSc**

PRSYM23: Treat to Target

Role: Speaker

PRSYM23: Collaborative/Translational Research

Role: Speaker

Disclosure: No financial relationships with ineligible companies to disclose

**Smitherman, Emily, MD, MS**

PRSYM23: Contemporary Best Practices for Childhood-Onset Lupus

Role: Speaker

Disclosure: No financial relationships with ineligible companies to disclose



## 2023 ACR Pediatric Rheumatology Symposium Faculty Disclosures Word

---

### **Son, Mary Beth, MD**

PRSYM23: Committee Member Disclosure

Role: Committee Member

PRSYM23: Vasculitis

Role: Moderator

Disclosure: No financial relationships with ineligible companies to disclose

### **Su, Helen, MD, PhD**

PRSYM23: Anti-IFN antibodies in Severe COVID-19

Role: Speaker

Disclosure: Amgen, stock holdings (Ongoing); Avanos Medical, stock holdings (Ongoing); Eli Lilly, stock holdings (Ongoing); Pfizer, stock holdings (Ongoing); Procter & Gamble Co., stock holdings (Ongoing); Viatrix Inc, stock holdings (Ongoing); Zimmer Biomet Holdings, stock holdings (Ongoing)

### **Swart, Joost, MD, PhD**

PRSYM23: Treatment Withdrawal in Juvenile Idiopathic Arthritis

Role: Speaker

Disclosure: No financial relationships with ineligible companies to disclose

### **Taxter, Alysha, MD, MS**

PRSYM23: Committee Member Disclosure

Role: Committee Member

PRSYM23: Quality Improvement/Patient-Reported Outcomes

Role: Moderator

Disclosure: No financial relationships with ineligible companies to disclose

### **Torok, Kathryn, MD**

PRSYM23: Scleroderma – Single Cell Omics

Role: Speaker

Plenary Session: Single Cell RNA Sequencing Analysis of the Skin to Evaluate the Effect of Autologous Stem Cell Transplant on Fibroblast Populations in Juvenile Onset Systemic Sclerosis

Role: Presenting Author

Disclosure: No financial relationships with ineligible companies to disclose

### **Utz, Paul, MD**

PRSYM23: Autoantibodies in COVID-19

Role: Speaker

Disclosure: No financial relationships with ineligible companies to disclose

## 2023 ACR Pediatric Rheumatology Symposium Faculty Disclosures Word

---

**Vastert, Sebastiaan, MD, PhD**

PRSYM23: Early Introduction of Biologics in Systemic JIA: Its Impact on Disease Course and Long-term Outcome

Role: Speaker

Disclosure: Novartis, 6 (Ongoing); SOBI, 5 (Ongoing), 6 (Ongoing)

**Verstegen, Ruud, MD, PhD**

PRSYM23: HLA-Associated Drug Response

Role: Speaker

Disclosure: No financial relationships with ineligible companies to disclose

**Wahezi, Dawn, MD, MS, RhMSUS**

PRSYM23: Clinical Updates in Juvenile Dermatomyositis Related Calcinosis

Role: Speaker

Disclosure: No financial relationships with ineligible companies to disclose

**White, Patience, MD, MA**

PRSYM23: Defining & Implementing High-Quality Transitional Care in Pediatric Rheumatology

Role: Speaker

Disclosure: Pfizer, I own stock (Ongoing)

**Wibrand, Camilla, MBBS**

Plenary Session: Analysis of Patients with Juvenile Dermatomyositis Compared to Healthy Controls Using CITE-seq Identifies Differences in Cell Composition and Gene and Epitope Expression

Role: Presenting Author

Disclosure: AMBU, 11 (Ongoing); GenMab, 11 (Ongoing); Lundbeck, 11 (Ongoing); NovoNordisk, 11 (Ongoing)

**Wise, Denisha**

PRSYM23: Committee Member Disclosure

Role: Staff

Disclosure: No financial relationships with ineligible companies to disclose

**Woo, Jennifer, PhD, MPH**

PRSYM23: Update on Disparities in Pediatric Rheumatology

Role: Speaker

Disclosure: No financial relationships with ineligible companies to disclose

## 2023 ACR Pediatric Rheumatology Symposium Faculty Disclosures Word

---

**Yi, Belina, DO**

Plenary Session: Treatment Response and Outcomes of 63 Cases of Juvenile Dermatomyositis-Associated Calcinosis

Role: Presenting Author

Disclosure: No financial relationships with ineligible companies to disclose

**Zhang, Emily, BS**

Plenary Session: Real-World Application of the Pediatric Glucocorticoid Toxicity Index in Children with Lupus Nephritis: A Feasibility and Initial Validation Study

Role: Presenting Author

Disclosure: No financial relationships with ineligible companies to disclose